Scientific

Event Publication Document
Why Choose? DARPin Miniproteins as Isotope-Agnostic Vector for Targeted Alpha Therapies
[²¹²Pb] Pb-MP0712 in patients with small cell lung cancer and other Delta-like ligand 3-expressing solid tumors: A phase 1/2a study to assess safety, tolerability, and efficacy
Presentation by Dr. Ticiana Leal (Emory Winship Cancer Institute) of the MP0712 trial-in-progress
A phase 1/2a study to assess safety, tolerability, and efficacy of [²¹²Pb]Pb-MP0712 in patients with small cell lung cancer (SCLC) and other Delta-like ligand 3 (DLL3) expressing solid tumors
Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC)
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
Logic-Gated Switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer – MP0632
Logic-gated Switch-DARPin-based immune-cell engagers guided by data-driven tumor-antigen profiling: A computational workflow for the development of cancer immunotherapies
Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC)
DARPins for Targeted Alpha Therapy -From promising MP0712 first in-human data to opportunities for next Radio-DARPin candidates

Investors